https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
IOZK
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
IOZK2016-02-01 13:56:132020-05-27 11:44:02IOZK Beitrag in der Fachzeitschrift für Orthomolekulare Medizin, Sonderheft: Onkologie
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-01-14 / Front Immunol 2015;6:663
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-01-14 / Front Immunol 2015;6:6632016-01-14 00:00:002021-11-15 13:26:00Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
IOZK
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
IOZK2015-10-12 16:50:102019-02-12 16:51:19Bericht von Prof. Dr. Schirrmacher im International Journal of Oncology zu den Erkenntnissen der Tumor-reaktiven T-Zell-Memory im Knochenmark
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-10-05 / Expert Opin Biol Ther 2015;15(12):1757-71
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-10-05 / Expert Opin Biol Ther 2015;15(12):1757-712015-10-05 00:00:002021-11-15 16:52:53Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-09-11 / Oncoimmunology 2016 Feb;5(2):e1083669
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-09-11 / Oncoimmunology 2016 Feb;5(2):e10836692015-09-11 00:00:002021-11-15 13:26:23Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
IOZK
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
IOZK2015-09-01 16:53:062019-02-12 16:53:40Stefaan Van Gool wechselt von der Universität Leuven zum IOZK
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-08-27 / Biomed Res Int 2015;2015:842923
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-08-27 / Biomed Res Int 2015;2015:8429232015-08-27 00:00:002021-11-15 13:26:51Tumour Relapse Prediction Using Multiparametric MR Data Recorded during Follow-Up of GBM Patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
IOZK
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
IOZK2015-08-12 16:59:282019-02-12 17:01:22Neue Antikörper für die immunologische Krebstherapie zugelassen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
IOZK
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
IOZK2015-07-03 17:04:122019-02-12 17:04:44ZEIT-Beilage: Leben mit Krebs mit einem Beitrag über das IOZK und der IOZK Immuntherapie
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-06-17 / Front Oncol 2015;5:98
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-06-17 / Front Oncol 2015;5:982015-06-17 00:00:002021-11-15 13:27:21Brain Tumor Immunotherapy: What have We Learned so Far?
